Requip News and Research

RSS
Parkinson's disease medications could lead to impulse control disorders

Parkinson's disease medications could lead to impulse control disorders

Actavis receives FDA approval for Ropinirole ER Tablets

Actavis receives FDA approval for Ropinirole ER Tablets

Parkinson's disease drugs may lead to impulse control disorders

Parkinson's disease drugs may lead to impulse control disorders

Dopamine agonists used in treatment of Parkinson's disease may lead to impulse control disorders

Dopamine agonists used in treatment of Parkinson's disease may lead to impulse control disorders

French guy says Parkinson’s drug induced gambling and gay sex addiction, tries to sue GSK for $610,000

French guy says Parkinson’s drug induced gambling and gay sex addiction, tries to sue GSK for $610,000

Patients with advanced Parkinson's disease prefer dopamine agonists, shows review

Patients with advanced Parkinson's disease prefer dopamine agonists, shows review

Reducing DA dosage causes acute withdrawal symptoms in Parkinson's patients

Reducing DA dosage causes acute withdrawal symptoms in Parkinson's patients

European markets for Parkinson's disease therapeutics to reach $2.28 billion in 2015

European markets for Parkinson's disease therapeutics to reach $2.28 billion in 2015

Tarsa Therapeutics receives license for Phase III oral calcitonin program

Tarsa Therapeutics receives license for Phase III oral calcitonin program

Save money wih generics

Save money wih generics

FDA approves first generic versions of Requip (ropinirole hydrochloride)

FDA approves first generic versions of Requip (ropinirole hydrochloride)

Requip significantly reduces periodic leg movements in patients with restless legs syndrome

Requip significantly reduces periodic leg movements in patients with restless legs syndrome